1171009-96-3

Usage

Uses

Used in Organic Light-Emitting Diodes (OLEDs) Industry:
Ir(PPy)2(tmd) is utilized as a photosensitizer for its ability to efficiently convert light energy into electrical energy, which is crucial for the operation of OLEDs. Its strong photoluminescence and efficient energy transfer properties make it an ideal candidate for improving the performance and efficiency of OLEDs.
Used in Chemistry and Materials Science Research:
Ir(PPy)2(tmd) serves as a valuable compound in research settings, where its unique properties are explored for potential applications in various chemical reactions and material fabrication processes. Ir(PPy)2(tmd)'s stability, photophysical properties, and coordination behavior make it a subject of interest for scientists looking to innovate in these fields.

Upstream product

• 23203-93-2 (Z)-2,2,6,6-tetramethylheptane-3,5-dione 
• 1118-71-4 2,2,6,6-tetramethylheptane-3,5-dione 

Relevant academic research and scientific papers

Screening structure-property correlations and device performance of Ir(iii) complexes in multi-layer PhOLEDs

The structure-property correlations of a set of heteroleptic red- and green-emitting Ir(iii) complexes with different temperature sensitivities and charge trapping capabilities are described, revealing superb performance in multi-layer phosphorescent organic light-emitting diodes (PhOLEDs) expressed by very high maximum luminous efficiencies up to 36.8 cd A-1. Using 2-phenylpyridine and with 2-(naphthalen-1-yl)pyridine as the CN ligand, the resulting red emitting complex featured a maximum luminous efficiency of 10.8 cd A-1; one of the most excellent device performances within this class of red Ir(iii) emitters.

Sulfur-Coordinated Organoiridium(III) Complexes Exert Breast Anticancer Activity via Inhibition of Wnt/β-Catenin Signaling

The sulfur-coordinated organoiridium(III) complexes pbtIrSS and ppyIrSS, which contain C,N and S,S (dithione) chelating ligands, were found to inhibit breast cancer tumorigenesis and metastasis by targeting Wnt/β-catenin signaling for the first time. Treatment with pbtIrSS and ppyIrSS induces the degradation of LRP6, thereby decreasing the protein levels of DVL2, β-catenin and activated β-catenin, resulting in downregulation of Wnt target genes CD44 and survivin. Additionally, pbtIrSS and ppyIrSS can suppress cell migration and invasion of breast cancer cells. Furthermore, both complexes show the ability to inhibit sphere formation and mediate the stemness properties of breast cancer cells. Importantly, pbtIrSS exerts potent anti-tumor and anti-metastasis effects in mouse xenograft models through the blockage of Wnt/β-catenin signaling. Taken together, our results indicate that pbtIrSS has great potential to be developed as a breast cancer therapeutic agent with a novel mechanism.